title: Factors predictive of recurrence after surgery for gastric cancer followed by adjuvant S-1 chemotherapy.
abstract: BACKGROUND
  The Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC) demonstrated that S-1(TS-1, an oral fluoropyrimidine) was effective as adjuvant chemotherapy for patients with pathological stage II or III gastric cancer who underwent curative gastrectomy. The objective of this study was to clarify the risk factors for recurrence in patients who received S-1 adjuvant chemotherapy.
  
  
  METHODS
  We retrospectively analyzed the factors predicting recurrence in 77 patients with stage II or III gastric cancer who received S-1 chemotherapy following R0 gastrectomy between April 2003 and October 2008.
  
  
  RESULTS
  The tumor diameter, macroscopic appearance, and presence of lymph node metastasis were significant factors predictive of recurrence identified by the univariate analysis. Moreover, the tumor diameter was an independent risk factor identified by the multivariate analysis.
  
  
  CONCLUSIONS
  It is necessary to establish a chemotherapeutic regimen for patients with stage II/III gastric cancers with large tumor diameter.
authors.affiliation: Department of Surgery, Gastroenterological Center, Yokohama City University, Minami-ku, Yokohama, Japan. tomoko_oct5@hotmail.com
authors.forename: Tomoko
authors.initials: T
authors.lastname: Wada
authors.forename: Chikara
authors.initials: C
authors.lastname: Kunisaki
authors.forename: Shinichi
authors.initials: S
authors.lastname: Hasegawa
authors.forename: Ryo
authors.initials: R
authors.lastname: Takagawa
authors.forename: Masashi
authors.initials: M
authors.lastname: Momiyama
authors.forename: Takashi
authors.initials: T
authors.lastname: Kosaka
authors.forename: Hirochika
authors.initials: H
authors.lastname: Makino
authors.forename: Hidetaka Andrew
authors.initials: HA
authors.lastname: Ono
authors.forename: Takashi
authors.initials: T
authors.lastname: Oshima
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Akiyama
authors.forename: Itaru
authors.initials: I
authors.lastname: Endo
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000188:drug therapy / Q000601:surgery; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000627:therapeutic use*; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D015996:Survival Rate; D005641:Tegafur / Q000627:therapeutic use*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid